Christiane E. Whetstone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christiane E. Whetstone has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Gail M. Gauvreau
Division of Respirology, Department of Medicine McMaster University Hamilton Ontario Canada
7 shared publications - Maral Ranjbar
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada
7 shared publications - Ruth P. Cusack
Department of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada
5 shared publications Gail Gauvreau
McMaster University, Hamilton, Canada
3 shared publications- Hafsa Omer
Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada
3 shared publications Imran Satia
McMaster University, Hamilton, Canada
3 shared publications
Latest Publications
- Open Access
- 11 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2312
Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets
Asthma is a chronic respiratory condition predominantly driven by a type 2 immune response. Epithelial-derived alarmins such as thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25 orchestrate the activation of downstream Th2 cells and group 2 innate lymphoid cells (ILC2s), along with other immune effector cells. While these alarmins are produced in response to inhaled triggers, such as allergens, respiratory pathogens or particulate matter, disproportionate alarmin production by airway epithelial cells can lead to asthma exacerbations. With alarmins produced upstream of the type 2 inflammatory cascade, understanding the pathways by which these alarmins are regulated and expressed is critical to further explore new therapeutics for the treatment of asthmatic patients. This review emphasizes the critical role of airway epithelium and epithelial-derived alarmins in asthma pathogenesis and highlights the potential of targeting alarmins as a promising therapeutic to improve outcomes for asthma patients.
- 11 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2312
Open AccessRegulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets
Asthma is a chronic respiratory condition predominantly driven by a type 2 immune response. Epithelial-derived alarmins such as thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25 orchestrate the activation of downstream Th2 cells and group 2 innate lymphoid cells (ILC2s), along with other immune effector cells. While these alarmins are produced in response to inhaled triggers, such as allergens, respiratory pathogens or particulate matter, disproportionate alarmin production by airway epithelial cells can lead to asthma exacerbations. With alarmins produced upstream of the type 2 inflammatory cascade, understanding the pathways by which these alarmins are regulated and expressed is critical to further explore new therapeutics for the treatment of asthmatic patients. This review emphasizes the critical role of airway epithelium and epithelial-derived alarmins in asthma pathogenesis and highlights the potential of targeting alarmins as a promising therapeutic to improve outcomes for asthma patients.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA4013
Higher inflammatory eosinophil levels in eosinophilic bronchitis compared to mild allergic asthma
Rationale: Patients with chronic cough often can have eosinophilic bronchitis (EB) with asthma or non-asthmatic eosinophilic bronchitis, despite similar eosinophil levels to patients with allergic asthma (AA) without chronic cough. We investigated if the frequency of eosinophil subtypes in blood and sputum is different in AA compared to EB. Methods: Patients with EB (chronic cough, FEV1≥70% predicted, sputum eosinophils>2%) and patients with mild AA (FEV1≥70% predicted, methacholine PC20≤16mg/mL and skin-prick positive) provided blood and sputum that were stained for eosinophils (CD45+CD16-CD15+) expressing resident (rEOS:CD62L+CD123-) and inflammatory (iEOS:CD62L-CD123+) and activation marker CD69 and expressed as % of total eosinophils. Results: Blood (250μl and 300μl) and sputum (3.8% and 3.2%) eosinophils in AA and EB, respectively, were similar. EB had a significantly higher frequency of iEOS and CD123+ eosinophils in blood and sputum, and higher levels of CD69+ eosinophils in sputum. Conclusion: A higher frequency of iEOS in both circulation and airways together with elevated levels of the activation marker CD69 in sputum eosinophils of EB compared to AA demonstrates a higher overall level of activated eosinophils. It is unclear whether eosinophils contribute to the pathophysiology of EB, but ongoing clinical trials with anti-IL-5 therapy will determine their relationship to cough.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA4013
Higher inflammatory eosinophil levels in eosinophilic bronchitis compared to mild allergic asthma
Rationale: Patients with chronic cough often can have eosinophilic bronchitis (EB) with asthma or non-asthmatic eosinophilic bronchitis, despite similar eosinophil levels to patients with allergic asthma (AA) without chronic cough. We investigated if the frequency of eosinophil subtypes in blood and sputum is different in AA compared to EB. Methods: Patients with EB (chronic cough, FEV1≥70% predicted, sputum eosinophils>2%) and patients with mild AA (FEV1≥70% predicted, methacholine PC20≤16mg/mL and skin-prick positive) provided blood and sputum that were stained for eosinophils (CD45+CD16-CD15+) expressing resident (rEOS:CD62L+CD123-) and inflammatory (iEOS:CD62L-CD123+) and activation marker CD69 and expressed as % of total eosinophils. Results: Blood (250μl and 300μl) and sputum (3.8% and 3.2%) eosinophils in AA and EB, respectively, were similar. EB had a significantly higher frequency of iEOS and CD123+ eosinophils in blood and sputum, and higher levels of CD69+ eosinophils in sputum. Conclusion: A higher frequency of iEOS in both circulation and airways together with elevated levels of the activation marker CD69 in sputum eosinophils of EB compared to AA demonstrates a higher overall level of activated eosinophils. It is unclear whether eosinophils contribute to the pathophysiology of EB, but ongoing clinical trials with anti-IL-5 therapy will determine their relationship to cough.
- Open Access
- 11 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (12) , 6427
Immune Response Dynamics and Biomarkers in COVID-19 Patients
Background: The immune response dynamics in COVID-19 patients remain a subject of intense investigation due to their implications for disease severity and treatment outcomes. We examined changes in leukocyte levels, eosinophil activity, and cytokine profiles in patients hospitalized with COVID-19. Methods: Serum samples were collected within the first 10 days of hospitalization/confirmed infection and analyzed for eosinophil granule proteins (EGP) and cytokines. Information from medical records including comorbidities, clinical symptoms, medications, and complete blood counts were collected at the time of admission, during hospitalization and at follow up approximately 3 months later. Results: Serum levels of eotaxin, type 1 and type 2 cytokines, and alarmin cytokines were elevated in COVID-19 patients, highlighting the heightened immune response (p < 0.05). However, COVID-19 patients exhibited lower levels of eosinophils and eosinophil degranulation products compared to hospitalized controls (p < 0.05). Leukocyte counts increased consistently from admission to follow-up, indicative of recovery. Conclusion: Attenuated eosinophil activity alongside elevated chemokine and cytokine levels during active infection, highlights the complex interplay of immune mediators in the pathogenesis COVID-19 and underscores the need for further investigation into immune biomarkers and treatment strategies.
- 11 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (12) , 6427
Open AccessImmune Response Dynamics and Biomarkers in COVID-19 Patients
Background: The immune response dynamics in COVID-19 patients remain a subject of intense investigation due to their implications for disease severity and treatment outcomes. We examined changes in leukocyte levels, eosinophil activity, and cytokine profiles in patients hospitalized with COVID-19. Methods: Serum samples were collected within the first 10 days of hospitalization/confirmed infection and analyzed for eosinophil granule proteins (EGP) and cytokines. Information from medical records including comorbidities, clinical symptoms, medications, and complete blood counts were collected at the time of admission, during hospitalization and at follow up approximately 3 months later. Results: Serum levels of eotaxin, type 1 and type 2 cytokines, and alarmin cytokines were elevated in COVID-19 patients, highlighting the heightened immune response (p < 0.05). However, COVID-19 patients exhibited lower levels of eosinophils and eosinophil degranulation products compared to hospitalized controls (p < 0.05). Leukocyte counts increased consistently from admission to follow-up, indicative of recovery. Conclusion: Attenuated eosinophil activity alongside elevated chemokine and cytokine levels during active infection, highlights the complex interplay of immune mediators in the pathogenesis COVID-19 and underscores the need for further investigation into immune biomarkers and treatment strategies.
- Open Access
- 26 March 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (4) , 401
Multifactorial Causes and Consequences of TLSP Production, Function, and Release in the Asthmatic Airway
Disruption of the airway epithelium triggers a defensive immune response that begins with the production and release of alarmin cytokines. These epithelial-derived alarmin cytokines, including thymic stromal lymphopoietin (TSLP), are produced in response to aeroallergens, viruses, and toxic inhalants. An alarmin response disproportionate to the inhaled trigger can exacerbate airway diseases such as asthma. Allergens inhaled into previously sensitized airways are known to drive a T2 inflammatory response through the polarization of T cells by dendritic cells mediated by TSLP. Harmful compounds found within air pollution, microbes, and viruses are also triggers causing airway epithelial cell release of TSLP in asthmatic airways. The release of TSLP leads to the development of inflammation which, when unchecked, can result in asthma exacerbations. Genetic and inheritable factors can contribute to the variable expression of TSLP and the risk and severity of asthma. This paper will review the various triggers and consequences of TSLP release in asthmatic airways.
- 26 March 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (4) , 401
Open AccessMultifactorial Causes and Consequences of TLSP Production, Function, and Release in the Asthmatic Airway
Disruption of the airway epithelium triggers a defensive immune response that begins with the production and release of alarmin cytokines. These epithelial-derived alarmin cytokines, including thymic stromal lymphopoietin (TSLP), are produced in response to aeroallergens, viruses, and toxic inhalants. An alarmin response disproportionate to the inhaled trigger can exacerbate airway diseases such as asthma. Allergens inhaled into previously sensitized airways are known to drive a T2 inflammatory response through the polarization of T cells by dendritic cells mediated by TSLP. Harmful compounds found within air pollution, microbes, and viruses are also triggers causing airway epithelial cell release of TSLP in asthmatic airways. The release of TSLP leads to the development of inflammation which, when unchecked, can result in asthma exacerbations. Genetic and inheritable factors can contribute to the variable expression of TSLP and the risk and severity of asthma. This paper will review the various triggers and consequences of TSLP release in asthmatic airways.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1932
Eosinophil phenotypes in circulation and airways of asthmatics after inhaled allergen challenge.
Rationale: Anti-eosinophil therapies improve clinical measurements of asthma in parallel with full depletion of eosinophils in circulation but only partial depletion in airways. We examined eosinophil phenotypes across these compartments and after airway triggers. Methods: Blood and sputum were collected at baseline, and at 7hr and 24hrs after inhaled allergen and diluent challenges. Sputum cells and whole blood was stained for eosinophils (CD45+ CD16- CD15+). Resident (rEOS: CD62L+ CD123-) and inflammatory (iEOS: CD62L- CD123+) eosinophils were expressed as % of total eosinophils. Results: Blood and sputum eosinophils increased at 7hr and 24hrs post-allergen compared to diluent challenge (p CD62L+ CD123+ > CD62L-CD123- > CD62L- CD123+ (iEOS), and in sputum was CD62L-CD123- > CD62L- CD123+ (iEOS) > CD62L+ CD123- (rEOS) > CD62L+CD123+. Blood had significantly higher iEOS and rEOS compared to sputum at all time points (p<0.001). Post-allergen proportions of rEOS drifted downwards in blood and upwards in sputum, with opposite trends in iEOS populations. Conclusion: Higher CD62L-CD123+ (iEOS) and lowering of CD62L+CD123- (rEOS) in blood post-allergen reflects a priming and efflux of eosinophils into airways. The high proportion of CD62L-CD123- eosinophils in sputum could simply represent the post-migration and post-activated airway phenotype.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1932
Eosinophil phenotypes in circulation and airways of asthmatics after inhaled allergen challenge.
Rationale: Anti-eosinophil therapies improve clinical measurements of asthma in parallel with full depletion of eosinophils in circulation but only partial depletion in airways. We examined eosinophil phenotypes across these compartments and after airway triggers. Methods: Blood and sputum were collected at baseline, and at 7hr and 24hrs after inhaled allergen and diluent challenges. Sputum cells and whole blood was stained for eosinophils (CD45+ CD16- CD15+). Resident (rEOS: CD62L+ CD123-) and inflammatory (iEOS: CD62L- CD123+) eosinophils were expressed as % of total eosinophils. Results: Blood and sputum eosinophils increased at 7hr and 24hrs post-allergen compared to diluent challenge (p CD62L+ CD123+ > CD62L-CD123- > CD62L- CD123+ (iEOS), and in sputum was CD62L-CD123- > CD62L- CD123+ (iEOS) > CD62L+ CD123- (rEOS) > CD62L+CD123+. Blood had significantly higher iEOS and rEOS compared to sputum at all time points (p<0.001). Post-allergen proportions of rEOS drifted downwards in blood and upwards in sputum, with opposite trends in iEOS populations. Conclusion: Higher CD62L-CD123+ (iEOS) and lowering of CD62L+CD123- (rEOS) in blood post-allergen reflects a priming and efflux of eosinophils into airways. The high proportion of CD62L-CD123- eosinophils in sputum could simply represent the post-migration and post-activated airway phenotype.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1931
Surface receptor expression on circulating and airway eosinophils after inhaled allergen challenge
Rationale: Eosinophilia is an important biomarker for tracking disease severity and the response to therapy in asthmatic patients. However, differences in response to therapy between circulating and airway eosinophils highlight the need to characterize eosinophil phenotypes. Methods: 11 mild allergic asthmatics underwent inhaled allergen and diluent challenges. Whole blood and sputum samples were collected 24hr before challenge and post-challenge at 7hr and 24hr, and stained for eosinophils (CD45+ CD16- CD15+) and surface receptors for cytokines CD125, CD123; chemokines; adhesion molecules VLA-4 (CD49d), L-selectin (CD62L); immunoregulatory receptor Siglec 8; and activation markers (CD66b, CD63, CD69). Eosinophils +ve for each receptor were expressed as a % of total eosinophils. Results: At baseline there was a higher % of eosinophils +ve for CD123, CD62L, CD49d, Siglec 8, CCR3, CD63 and CD69 in blood compared to sputum. Allergen challenge reduced FEV1 by ≥ 20%. Post-allergen challenge, the % of Siglec 8 +ve eosinophils increased in sputum compared to diluent (p<0.05). Compared to pre-allergen baseline the % eosinophils +ve for CD69 and CD123 increased in blood, and CD123 decreased in sputum post-allergen, but these changes were not significantly different than diluent. Conclusion: Receptors to ligands for eosinophil activation and recruitment are downregulated in sputum eosinophils, confirming previous activation of these pathways. Recruitment of Siglec 8 +ve eosinophils to airways post-allergen challenge may be a mechanism for local immunoregulation.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1931
Surface receptor expression on circulating and airway eosinophils after inhaled allergen challenge
Rationale: Eosinophilia is an important biomarker for tracking disease severity and the response to therapy in asthmatic patients. However, differences in response to therapy between circulating and airway eosinophils highlight the need to characterize eosinophil phenotypes. Methods: 11 mild allergic asthmatics underwent inhaled allergen and diluent challenges. Whole blood and sputum samples were collected 24hr before challenge and post-challenge at 7hr and 24hr, and stained for eosinophils (CD45+ CD16- CD15+) and surface receptors for cytokines CD125, CD123; chemokines; adhesion molecules VLA-4 (CD49d), L-selectin (CD62L); immunoregulatory receptor Siglec 8; and activation markers (CD66b, CD63, CD69). Eosinophils +ve for each receptor were expressed as a % of total eosinophils. Results: At baseline there was a higher % of eosinophils +ve for CD123, CD62L, CD49d, Siglec 8, CCR3, CD63 and CD69 in blood compared to sputum. Allergen challenge reduced FEV1 by ≥ 20%. Post-allergen challenge, the % of Siglec 8 +ve eosinophils increased in sputum compared to diluent (p<0.05). Compared to pre-allergen baseline the % eosinophils +ve for CD69 and CD123 increased in blood, and CD123 decreased in sputum post-allergen, but these changes were not significantly different than diluent. Conclusion: Receptors to ligands for eosinophil activation and recruitment are downregulated in sputum eosinophils, confirming previous activation of these pathways. Recruitment of Siglec 8 +ve eosinophils to airways post-allergen challenge may be a mechanism for local immunoregulation.
- Open Access
Gene Polymorphisms of Epithelial Cell-Derived Alarmins and Their Effects on Protein Levels and Disease Severity in Patients with COVID-19
Background: The immune response in COVID-19 is characterized by the release of alarmin cytokines, which play crucial roles in immune activation and inflammation. The interplay between these cytokines and genetic variations may influence disease severity and outcomes, while sex differences might further contribute to variations in the immune response. Methods: We measured the levels of alarmin cytokines in a cohort of COVID-19 and non-COVID-19 patients using a sensitive Meso Scale Discovery system. Additionally, we conducted an SNP analysis to identify genetic variations within the IL-33 and TSLP genes. The association between these genetic variations, cytokine production, and COVID-19 severity was examined. Results: Our findings revealed elevated levels of IL-33 and IL-25 in COVID-19-positive patients compared to COVID-19-negative patients (p < 0.05), indicating their potential as therapeutic targets for disease modulation. Moreover, a minor allele within the IL-33 gene (rs3939286) was found to be associated with a protective effect against severe COVID-19 (p < 0.05), and minor alleles of the TSLP gene (rs2289276 and rs13806933) were found to significantly reduce TSLP protein levels in serum (p < 0.05). Sex-specific effects of TSLP and IL-33 SNPs were observed, suggesting a potential influence of sex hormones and genetic variations on the regulation of cytokine production. Conclusion: The present study highlights the importance of alarmin cytokines and genetic variations in COVID-19 severity, providing valuable insights into personalized treatment approaches. Our results suggest that targeting alarmin cytokines may offer potential therapeutic benefits in managing COVID-19. Furthermore, the sex-specific effects of genetic variations emphasize the need to consider individual genetic profiles and sex differences when designing targeted interventions.
Open AccessGene Polymorphisms of Epithelial Cell-Derived Alarmins and Their Effects on Protein Levels and Disease Severity in Patients with COVID-19
Background: The immune response in COVID-19 is characterized by the release of alarmin cytokines, which play crucial roles in immune activation and inflammation. The interplay between these cytokines and genetic variations may influence disease severity and outcomes, while sex differences might further contribute to variations in the immune response. Methods: We measured the levels of alarmin cytokines in a cohort of COVID-19 and non-COVID-19 patients using a sensitive Meso Scale Discovery system. Additionally, we conducted an SNP analysis to identify genetic variations within the IL-33 and TSLP genes. The association between these genetic variations, cytokine production, and COVID-19 severity was examined. Results: Our findings revealed elevated levels of IL-33 and IL-25 in COVID-19-positive patients compared to COVID-19-negative patients (p < 0.05), indicating their potential as therapeutic targets for disease modulation. Moreover, a minor allele within the IL-33 gene (rs3939286) was found to be associated with a protective effect against severe COVID-19 (p < 0.05), and minor alleles of the TSLP gene (rs2289276 and rs13806933) were found to significantly reduce TSLP protein levels in serum (p < 0.05). Sex-specific effects of TSLP and IL-33 SNPs were observed, suggesting a potential influence of sex hormones and genetic variations on the regulation of cytokine production. Conclusion: The present study highlights the importance of alarmin cytokines and genetic variations in COVID-19 severity, providing valuable insights into personalized treatment approaches. Our results suggest that targeting alarmin cytokines may offer potential therapeutic benefits in managing COVID-19. Furthermore, the sex-specific effects of genetic variations emphasize the need to consider individual genetic profiles and sex differences when designing targeted interventions.
- Open Access
The Genetic Factors of the Airway Epithelium Associated with the Pathology of Asthma
Asthma is a chronic disease of the airways characterized by inflammation, tightened muscles, and thickened airway walls leading to symptoms such as shortness of breath, chest tightness, and cough in patients. The increased risk of asthma in children of asthmatics parents supports the existence of genetic factors involved in the pathogenesis of this disease. Genome-wide association studies have discovered several single nucleotide polymorphisms associated with asthma. These polymorphisms occur within several genes and can contribute to different asthma phenotypes, affect disease severity, and clinical response to different therapies. The complexity in the etiology of asthma also results from interactions between environmental and genetic factors. Environmental exposures have been shown to increase the prevalence of asthma in individuals who are genetically susceptible. This review summarizes what is currently known about the genetics of asthma in relation to risk, response to common treatments, and gene-environmental interactions.
Open AccessThe Genetic Factors of the Airway Epithelium Associated with the Pathology of Asthma
Asthma is a chronic disease of the airways characterized by inflammation, tightened muscles, and thickened airway walls leading to symptoms such as shortness of breath, chest tightness, and cough in patients. The increased risk of asthma in children of asthmatics parents supports the existence of genetic factors involved in the pathogenesis of this disease. Genome-wide association studies have discovered several single nucleotide polymorphisms associated with asthma. These polymorphisms occur within several genes and can contribute to different asthma phenotypes, affect disease severity, and clinical response to different therapies. The complexity in the etiology of asthma also results from interactions between environmental and genetic factors. Environmental exposures have been shown to increase the prevalence of asthma in individuals who are genetically susceptible. This review summarizes what is currently known about the genetics of asthma in relation to risk, response to common treatments, and gene-environmental interactions.
- Top Cited PapersOpen Access
The Role of Airway Epithelial Cell Alarmins in Asthma
The airway epithelium is the first line of defense for the lungs, detecting inhaled environmental threats through pattern recognition receptors expressed transmembrane or intracellularly. Activation of pattern recognition receptors triggers the release of alarmin cytokines IL-25, IL-33, and TSLP. These alarmins are important mediators of inflammation, with receptors widely expressed in structural cells as well as innate and adaptive immune cells. Many of the key effector cells in the allergic cascade also produce alarmins, thereby contributing to the airways disease by driving downstream type 2 inflammatory processes. Randomized controlled clinical trials have demonstrated benefit when blockade of TSLP and IL-33 were added to standard of care medications, suggesting these are important new targets for treatment of asthma. With genome-wide association studies demonstrating associations between single-nucleotide polymorphisms of the TSLP and IL-33 gene and risk of asthma, it will be important to understand which subsets of asthma patients will benefit most from anti-alarmin therapy.
Top Cited PapersOpen AccessThe Role of Airway Epithelial Cell Alarmins in Asthma
The airway epithelium is the first line of defense for the lungs, detecting inhaled environmental threats through pattern recognition receptors expressed transmembrane or intracellularly. Activation of pattern recognition receptors triggers the release of alarmin cytokines IL-25, IL-33, and TSLP. These alarmins are important mediators of inflammation, with receptors widely expressed in structural cells as well as innate and adaptive immune cells. Many of the key effector cells in the allergic cascade also produce alarmins, thereby contributing to the airways disease by driving downstream type 2 inflammatory processes. Randomized controlled clinical trials have demonstrated benefit when blockade of TSLP and IL-33 were added to standard of care medications, suggesting these are important new targets for treatment of asthma. With genome-wide association studies demonstrating associations between single-nucleotide polymorphisms of the TSLP and IL-33 gene and risk of asthma, it will be important to understand which subsets of asthma patients will benefit most from anti-alarmin therapy.
- Open Access
Regulation of Eosinophilia in Asthma—New Therapeutic Approaches for Asthma Treatment
Asthma is a complex and chronic inflammatory disease of the airways, characterized by variable and recurring symptoms, reversible airflow obstruction, bronchospasm, and airway eosinophilia. As the pathophysiology of asthma is becoming clearer, the identification of new valuable drug targets is emerging. IL-5 is one of these such targets because it is the major cytokine supporting eosinophilia and is responsible for terminal differentiation of human eosinophils, regulating eosinophil proliferation, differentiation, maturation, migration, and prevention of cellular apoptosis. Blockade of the IL-5 pathway has been shown to be efficacious for the treatment of eosinophilic asthma. However, several other inflammatory pathways have been shown to support eosinophilia, including IL-13, the alarmin cytokines TSLP and IL-33, and the IL-3/5/GM-CSF axis. These and other alternate pathways leading to airway eosinophilia will be described, and the efficacy of therapeutics that have been developed to block these pathways will be evaluated.
Open AccessRegulation of Eosinophilia in Asthma—New Therapeutic Approaches for Asthma Treatment
Asthma is a complex and chronic inflammatory disease of the airways, characterized by variable and recurring symptoms, reversible airflow obstruction, bronchospasm, and airway eosinophilia. As the pathophysiology of asthma is becoming clearer, the identification of new valuable drug targets is emerging. IL-5 is one of these such targets because it is the major cytokine supporting eosinophilia and is responsible for terminal differentiation of human eosinophils, regulating eosinophil proliferation, differentiation, maturation, migration, and prevention of cellular apoptosis. Blockade of the IL-5 pathway has been shown to be efficacious for the treatment of eosinophilic asthma. However, several other inflammatory pathways have been shown to support eosinophilia, including IL-13, the alarmin cytokines TSLP and IL-33, and the IL-3/5/GM-CSF axis. These and other alternate pathways leading to airway eosinophilia will be described, and the efficacy of therapeutics that have been developed to block these pathways will be evaluated.